The Summary
Researchers conducted a systematic review and meta-analysis of 16 observational studies, including 473 individuals with autism spectrum disorder (ASD) and 514 neurotypical controls, to compare short-chain fatty acid (SCFA) profiles. The results revealed significant elevations of specific SCFAs—valeric, hexanoic, and isobutyric acids—in individuals with ASD. While common SCFAs like acetic, propionic, and butyric acids showed no overall differences, variations appeared depending on the sample type tested. These findings confirm that distinct metabolic pathways related to microbial dysbiosis are altered in ASD.
Why this is interesting
Scientists have long suspected a link between the microbiome and autism, but previous studies on metabolic byproducts were inconsistent. By pooling data from multiple studies, researchers confirmed that people with autism have distinct chemical signatures, specifically higher levels of certain lesser-known short-chain fatty acids. For readers, this reinforces the profound biological link between the digestive system and neurological development. While it does not suggest that treatments can cure autism, it opens the door for using these specific fatty acids as potential biomarkers for future therapies.